Hypothetically, if crizotinib is developed using a basket trial, the basket trial would be composed of sub-trial 1 with NSCLC, sub-trial 2 with ALCL, and sub-trial 3 with IMT, all with ALK fusion-positive tumors. Here, ALK is linked to anaplastic large cell lymphoma.